Objectives: The purpose of this study was to evaluate the analgesic effects of perioperative gabapentin on postoperative acute and chronic pain after coronary artery bypass graft (CABG) surgery with median sternotomy and internal mammary artery harvesting.
Design: A double-blind randomized clinical study.
Setting: A single-academic hospital.
Participants: Patients with ischemic heart disease who were scheduled to undergo CABG surgery.
Interventions: Forty patients were allocated randomly into 2 groups; the gabapentin group (n = 20) received 1.2 g/d of oral gabapentin before and for 2 days after surgery, and the placebo group (n = 20) received a placebo capsule instead. The primary outcome was to evaluate the effects of gabapentin on acute and chronic pain after surgery. The postoperative evaluation included the assessment of pain at rest and when coughing, intravenous tramadol usage, postoperative morbidities, and side effects of gabapentin. Postoperative analgesia at 6, 12, 18, 24, 48, and 72 hours after extubation and at discharge was evaluated with the visual analog scale. The assessment of postoperative pain at the 1- and 3-month follow-ups was performed using a numeric rating scale.
Main Results: Postoperative pain scores at 1, 2, and 3 days were significantly lower in the gabapentin group when compared with the placebo group (p < 0.05). Pain scores at 1 and 3 months postoperatively were lower in the gabapentin group than in the placebo group (p > 0.05). Consumption of intravenous tramadol given as rescue analgesic within 24 hours after extubation in the gabapentin group was 99.0 ± 53.8 mg versus 149.4 ± 72.5 mg in the placebo group (p < 0.05). There were no differences in the incidence of side effects and time to extubation between the groups.
Conclusions: Gabapentin significantly reduced the intensity of pain and tramadol consumption in the early postoperative period after CABG surgery. Pain scores at 1 and 3 months after surgery were low in both groups, with no significant difference between the groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.jvca.2010.11.017 | DOI Listing |
BMC Psychiatry
January 2025
Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran.
Introduction: Mental disorders, such as anxiety and depression, significantly impacted global populations in 2019 and 2020, with COVID-19 causing a surge in prevalence. They affect 13.4% of the people worldwide, and 21% of Iranians have experienced them.
View Article and Find Full Text PDFJt Dis Relat Surg
January 2025
Balıkesir Üniversitesi Tıp Fakültesi Ortopedi ve Travmatoloji Anabilim Dalı, 10185 Altıeylül, Balıkesir, Türkiye.
Objectives: This study evaluated the impact of different doses of gabapentin and pregabalin on fracture healing in a rat femoral shaft model, with histological, radiological, and biomechanical assessments.
Materials And Methods: Seventy male Wistar albino rats were divided into five groups: control, low-dose gabapentin (GBP-L, 300 mg/day), high-dose gabapentin (GBP-H, 3600 mg/day), low-dose pregabalin (PRG-L, 150 mg/day), and high-dose pregabalin (PRG-H, 600 mg/day), based on human equivalent doses. Bilateral femoral fractures were induced; the right femurs were prepared for radiological examination using microtomography, followed by histological analysis, whereas the left femurs were allocated for biomechanical testing.
J Pharmacol Sci
January 2025
Department of Endocrinology, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China. Electronic address:
Elevated reactive species and AGEs contribute to deregulation of transcription factors e.g., NF-κB and Nrf2 in diabetic peripheral neuropathy (DPN).
View Article and Find Full Text PDFFront Pharmacol
December 2024
Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom.
Introduction: Chronic pelvic pain affects up to 24% of women worldwide and for up to 55% of these there is no associated pathology. Despite this there are no established treatments in this cohort. This is a secondary analysis of a randomised-controlled trial (GaPP2) to explore if there are measures which enable us to predict treatment outcome.
View Article and Find Full Text PDFPain
October 2024
Clinical Learning, Evidence, and Research Center, University of Washington, Seattle, WA, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!